| HOME >> BIOLOGY >> TECHNOLOGY |
Genetic disorders predisposing to atherosclerosis 317
Familial hypercholesterolemia (FH) 317
Apolipoprotein E (apoE) deficiency 319
Hypertension 319
Genetic factors for myocardial infarction 320
Acquired cardiovascular diseases 320
Coronary artery disease with angina pectoris 320
Ad5FGF-4 320
Ischemic heart disease with myocardial infarction 321
Myocardial repair with IGF-1 therapy 322
Metalloproteinase-2 inhibitor gene therapy 322
Congestive heart failure 323
Rationale of gene therapy in CHF 323
Beta-ARKct gene therapy 323
Intracoronary adenovirus-mediated gene therapy for CHF 324
AAV-mediated gene transfer for CHF 324
AngioCell gene therapy for CHF 325
nNOS gene transfer in CHF 325
Cardiomyopathies 325
Cardiac conduction disturbances 326
Gene transfer approaches for biological pacemakers 326
Genetically engineered biological pacemakers 326
Gene therapy and heart transplantation 327
Peripheral arterial disease 327
Incidence and clinical features 327
Current management 328
Gene therapy for peripheral arterial disease 328
Angiogenesis by gene therapy 328
HIF-1a gene therapy for peripheral arterial disease 328
HGF gene therapy for peripheral arterial disease 329
Ischemic neuropathy secondary to peripheral arterial disease 329
Prevention of restenosis after angioplasty 330
Antisense approaches 330
Gene therapy to prevent restenosis after angioplasty 330
Techniques of gene therapy for restenosis 332
NOS gene therapy for restenosis 332
hTIMP-1 gene therapy to prevent intimal hyperplasia 333
Maintaining vascular patency after surgery 333
Companies involved in gene therapy of cardiovascular diseases 334
Future prospects of gene therapy of cardiovascu
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |